The mAb portion of anti-HER2 ADCs is distinctly metabolized by proteolytic degradation within the cancer cells; changes in the binding-regions of the mAb impact the ADC/cancer cell interaction and can result in altered metabolism [144]. The gene discussed is ERBB2; the disease is cancer.